Lidocain-Egis (Lidocaine)

Lidocaine works by reversibly blocking voltage‑gated sodium channels on nerve cells. This inhibition prevents the rapid influx of sodium ions needed for depolarisation, thereby stopping the generation and propagation of pain signals. The effect is confined to the area of application, producing localized numbness without systemic anaesthesia.

The dose of Lidocain‑Egis is determined by the prescribing healthcare professional based on the specific indication, the size of the mucosal area to be treated, patient age, and overall health status. The prescriber will decide the amount and frequency of application to achieve effective pain relief while minimising the risk of toxicity.

Safety data for Lidocain‑Egis in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider before starting treatment.

To order Lidocain‑Egis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lidocain‑Egis contains lidocaine, an amide‑type local anesthetic with a rapid onset and moderate duration of action. Compared with benzocaine, another topical anesthetic, lidocaine generally provides a deeper level of numbness and a lower risk of methemoglobinemia. However, both agents share similar precautions regarding allergic reactions and systemic toxicity when used excessively.

Lidocain‑Egis should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use. Do not freeze the product, and keep it out of reach of children.

Lidocain‑Egis is applied directly to the oral mucosa using the supplied applicator or a clean fingertip. The recommended amount is spread evenly over the affected area, avoiding ingestion. Administration is performed by a healthcare professional or, when appropriate, by the patient following the prescriber's instructions.

The most serious risks include allergic reactions that can progress to anaphylaxis, methemoglobinemia which reduces the blood’s ability to carry oxygen, and cardiac toxicity such as arrhythmias or conduction disturbances, especially after large‑area or repeated applications that lead to systemic absorption.

Lidocain‑Egis should be avoided in individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics. Patients with severe cardiac conduction disorders, uncontrolled heart disease, or a history of methemoglobinemia should also refrain from using the product unless specifically directed by a qualified clinician.